4-[2,3-dihydro-1H-1-indenyl(methyl)amino]-1,2,3,4-tetrahydro-1-naphthalenone | 1213711-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 4-[2,3-dihydro-1H-1-indenyl(methyl)amino]-1,2,3,4-tetrahydro-1-naphthalenone
• 英文别名: 4-[2,3-dihydro-1H-inden-1-yl(methyl)amino]-3,4-dihydro-2H-naphthalen-1-one
• CAS: 1213711-23-9
• 化学式: C₂₀H₂₁NO
• 分子量: 291.393
• InChiKey: REOZAYVAGVYMBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-(2,3-dihydro-1H-1-indenylamino)-1,2,3,4-tetrahydro-1-naphthalenone 、 碘甲烷 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 48.0h， 以87%的产率得到4-[2,3-dihydro-1H-1-indenyl(methyl)amino]-1,2,3,4-tetrahydro-1-naphthalenone
  参考文献：
  名称：

  Synthesis and evaluation of dimeric 1,2,3,4-Tetrahydro-naphthalenylamine and Indan-1-ylamine derivatives with mast cell-stabilising and anti-allergic activity

  摘要：

  In a continuation of our studies into 4-Amino-3,4-dihydro-2H-naphthalen-1-ones as novel modulators of allergic and inflammatory phenomena, we have extended our work to include dimeric analogues. Of these derivatives, the most promising activity was seen with tertiary amine 58a, which exhibited potent mast cell-stabilising activity in vitro against a variety of stimuli and also in vivo against passive cutaneous anaphylaxis. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.09.020

文献信息

• COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS
  申请人：The General Hospital Corporation

  公开号：US20210059977A1

  公开（公告）日：2021-03-04

  Described herein are methods of treating neuron inflammation conditions, for example, amyotropic lateral sclerosis and prion disease, comprising administering a therapeutically effective amount of a combination of cromolyn or a cromolyn derivative compound and an anti-inflammatory agent.
• METHODS OF TREATING CYTOKINE RELEASE SYNDROME
  申请人：The General Hospital Corporation

  公开号：US20220218652A1

  公开（公告）日：2022-07-14

  The present disclosure relates to a method of treating at least one Cell-Associated Neurotoxicity Syndrome (ICANS), cancer-related cognitive impairment, Infusion Reaction Syndrome (IRS), Capillary Leak Syndrome (CLS), Tumor Lysis Syndrome (TLS), Macrophage Activation Syndrome (MAS), Systemic Inflammatory Response Syndrome (SIRS), Immune Reconstitution Inflammatory Syndrome (IRIS), Graft-Versus-Host Disease (GVHD), Acute Respiratory Distress Syndrome (ARDS), sepsis, Ebola, avian influenza, smallpox, Systemic Inflammatory Response Syndrome (SIRS), and Immune-related Adverse Events Syndrome (IrAES) in a subject in need thereof, comprising administering a mast cell stabilizer or a compound of Formula I or Formula II: Formula I, Formula II, wherein R 1 is halogen, OH, or —OC(O)C 1-5 alkyl R 2 and R 3 are each independently selected from CO 2 R 4 or CH 2 OR 5 ; R 4 is i L, Na, K, H, C 1-5 alkyl, or —CH 2 CO(C 1-5 alkyl); and R 5 is H or C(O)(C 1-5 alkyl), or a pharmaceutically acceptable salt thereof.
• Synthesis and evaluation of dimeric 1,2,3,4-Tetrahydro-naphthalenylamine and Indan-1-ylamine derivatives with mast cell-stabilising and anti-allergic activity
  作者：James W. Barlow、John J. Walsh

  DOI：10.1016/j.ejmech.2009.09.020

  日期：2010.1

  In a continuation of our studies into 4-Amino-3,4-dihydro-2H-naphthalen-1-ones as novel modulators of allergic and inflammatory phenomena, we have extended our work to include dimeric analogues. Of these derivatives, the most promising activity was seen with tertiary amine 58a, which exhibited potent mast cell-stabilising activity in vitro against a variety of stimuli and also in vivo against passive cutaneous anaphylaxis. (C) 2009 Elsevier Masson SAS. All rights reserved.